Evaluation of Time to Detection of Mycobacterium tuberculosis in Broth Culture as a Determinant for End Points in Treatment Trials-Reference-Cited by-同舟云学术

Evaluation of Time to Detection of Mycobacterium tuberculosis in Broth Culture as a Determinant for End Points in Treatment Trials

Published:2010-12 Issue:12 Volume:48 Page:4370-4376
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Weiner Marc¹,Prihoda Thomas J.²,Burman William³,Johnson John L.⁴,Goldberg Stefan⁵,Padayatchi Nesri⁶,Duran Paula¹,Engle Melissa¹,Muzanye Grace⁷,Mugerwa Roy D.⁷,Sturm A. Willem⁸

Affiliation:

1. Departments of Medicine

2. Pathology, University of Texas Health Science Center San Antonio, and VAMC, 7400 Merton Minter Blvd., San Antonio, Texas 78229-4404

3. Denver Public Health, 605 Bannock Street, Denver, Colorado 80204

4. Department of Medicine, Case Western Reserve University and University Hospitals Case Medical Center, The Uganda-Case Western Reserve University Research Collaboration, 10900 Euclid Blvd., Cleveland, Ohio 44106-4945

5. Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, 1600 Clifton Rd., NE, Atlanta, Georgia 30333

6. Departments of Community Health, CAPRISA, 719 Umbilo Road, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa

7. Uganda-Case Western Reserve University Research Collaboration, P.O. Box 663, Kampala, Uganda

8. Department of Medical Microbiology, 719 Umbilo Road, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa

Abstract

ABSTRACT Time to detection of Mycobacterium tuberculosis in broth culture was examined for utility as a treatment efficacy end point. Of 146 patients in a phase IIB trial, a decreased mean time to detection was found in 5 with treatment failure. Time to detection in an analysis-of-covariance model was associated with lung cavities, less intensive treatment, and differences in the bactericidal effects of treatment regimens.

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.00757-10

Reference17 articles.

1. Aber, V. R., and A. J. Nunn. 1978. Factors affecting relapse following short-course chemotherapy. Bull. Int. Union Tuberc. 53 : 260-264.

2. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

3. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

4. Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis

5. Dosing Schedules of 6-Month Regimens and Relapse for Pulmonary Tuberculosis

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial;The Journal of Infectious Diseases;2024-03-25

2. Clinically encountered growth phenotypes of tuberculosis-causing bacilli and their in vitro study: A review;Frontiers in Cellular and Infection Microbiology;2022-11-10

3. Longitudinal Model-Based Biomarker Analysis of Exposure-Response Relationships in Adults with Pulmonary Tuberculosis;Antimicrobial Agents and Chemotherapy;2021-09-17

4. A generalized Bayesian nonlinear mixed‐effects regression model for zero‐inflated longitudinal count data in tuberculosis trials;Pharmaceutical Statistics;2019-04-07

5. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial;The Lancet Respiratory Medicine;2019-03